Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 02, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Colorful Nanoprobes Make A Simple Test
Gold nanoparticles linked to single-stranded DNA create a simple but versatile genetic testing kit.
How Gene Expression Affects Facial Expressions
Researchers from USC have demonstrated how a mutation in TBX1 causes facial deformities associated with DiGeorge Syndrome.
Blood Test May Help Determine Psychosis Risk
A study led by University of North Carolina at Chapel Hill researchers represents an important step forward in the accurate diagnosis of people who are experiencing the earliest stages of psychosis.
Gene Expression Patterns in Pancreatic CTCs Revealed
Distinct patterns of gene expression in several groups of CTCs were identified, including significant differences from the primary tumor that may contribute to the ability to generate metastases and prove to be targets for improved treatment of the deadly tumor.
How Epigenetic Memory is Passed Across Generations
Researchers traced markers of gene repression through cell division and showed that both sperm and eggs transmit a memory of gene repression to embryos.
Spontaneous Mutations in Key Brain Gene are a Cause of Autism
In addition, there is a direct link between TBR1 and FOXP2, a well-known language-related protein, researchers report.
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles
Study reveals personalized risks for expansion from parent to child.
Genetics Reveals Patients Susceptible to Drug-induced Pancreatitis
Doctors have discovered that patients with a particular genetic variation are four times more likely to develop pancreatitis if they are prescribed a widely used group of drugs.
Blood Test To Diagnose Depression
Test identifies nine blood markers tied to depression; predicts who will benefit from therapy.
Genetic Testing for Prostate Cancer
Genetic testing can identify men at six-fold increased risk of prostate cancer.
Scroll Up
Scroll Down
Return
Multi Center Validation of a New Molecular Diagnostic Assay for Accurate and Rapid Screening of JAK2 V617F Mutation
Fabienne Hermitte, CSO, Ipsogen, speaking at the Molecular Diagnostics World Congress 2007
Date Posted: Monday, May 19, 2008
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Tuesday, October 07, 2008
IPSOGEN Expands its U.S. Presence Through Licensing Agreement with Quest Diagnostics
Ipsogen SA, a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Monday, October 06, 2008
Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results
The Company expects that by improving the accuracy of tumor grading, the test could spare tens of thousands chemotherapy treatments per year.
Monday, June 02, 2008
Ipsogen Announces Three Studies at the American Society of Clinical Oncology Meeting
The results from the studies extend the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer.
Monday, May 26, 2008
IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
IPSOGEN signed a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.
Monday, January 28, 2008
Ipsogen Reports Recommendation of JAK2V617F Mutation Screening in WHO 2008 Criteria and Point-of-Care Diagnostic Algorithms
The 2008 revision of the WHO document on the classification of CMPDs has incorporated new information on the molecular pathogenesis of BCR–ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.
Tuesday, January 22, 2008
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Tuesday, September 11, 2007
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
Thursday, August 16, 2007
Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
These results concern the identification on 323 patient samples.
Monday, February 27, 2006
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv